Ekterly

News

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

News

KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.

News

Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.